RespiFinder® DC 18 (RespiFinder DC plus)
- Adenovirus (AdV)
- Bordetella pertussis (B. pertussis)
- Chlamydophila pneumoniae (C. pneumoniae)
- Coronavirus 229E (Cor-229E)
- Coronavirus NL63 (Cor-NL63)
- Coronavirus OC43 (Cor-OC43)
- Human Metapneumovirus (hMPV)
- Influenza A (InfA)
- Influenza B (InfB)
- Legionella pneumophila (L. pneumophila)
- Mycoplasma pneumoniae (M. pneumoniae)
- Parainfluenza Type 1 (PIV-1)
- Parainfluenza Type 2 (PIV-2)
- Parainfluenza Type 3 (PIV-3)
- Parainfluenza Type 4 (PIV-4)
- Respiratory Syncytial Virus A (RSVA)
- Respiratory Syncytial Virus B (RSVB)
- Rhinovirus (RhV)
The RespiFinder® DC 18 Kit (previous name: RespiFinder DC plus) is a multiplex PCR test which can detect and differentiate 13 RNA viruses, 1 DNA virus as well as 4 bacteria in a single assay.
Detection of the various amplicons is accomplished by size-fractionation on a microfluidics electrophoresis system like the Experion (BioRad), QIAxcel (Qiagen), Bioanalyser (Agilent) and others.
- 14 viral + 4 bacterial pathogens in one assay
- As sensitive as monoplex Real Time PCR
- Contains a competitive internal amplification control
- Diagnosis within 6 hours
- Validated on QCMD panels
- CE-IVD labelled
Acute respiratory tract infection (RTI) is the most widespread type of acute infection in adults and children and is a significant cause of disease in immunocompromised patients. Both viruses and bacteria can cause acute RTI, and the number of causative agents is large as well as diverse. Multiparameter tests provide a fast and accurate means of molecular diagnostics. The RespiFinder® DC 18 Kit is a multiplex PCR test which can detect and differentiate 13 RNA viruses, 1 DNA virus as well as 4 bacteria in a single assay.
The RespiFinder® DC 18 assay is based on our proprietary MultiFinder technology, which allows a highly complex analysis of up to 25 targets in a single reaction. The RespiFinder® DC 18 assay includes a pre-amplification step which combines a reverse transcription step with a PCR to amplify the target DNA. Subsequently, a MLPA reaction is performed comprising of a probe hybridization step, a probe ligation step and a probe amplification step. Only two primers are used in the final PCR. Every target results in a PCR fragment of a specific length. The pre-amplification step is performed for all targets simultaneously (single tube), the target identification is performed in two separate panels.
- Nasopharyngeal aspirate/lavage
- swabs
- bronchoalveolar lavage (BAL)
- sputa
The Internal Amplification Control is a RNA transcript from the encephalomyocarditis (EMC) virus and is supplied as a control for the RNA/DNA isolation, the RespiFinder® DC 18 assay and to check for possible PCR inhibitors.
Detection of the various amplicons is accomplished by size-fractionation on a microfluidics electrophoresis system like the Experion (BioRad), QIAxcel (Qiagen), Bioanalyser (Agilent) and others.
Quality Control for Molecular Diagnostics (QCMD) is an international External Quality Assessment (EQA) provider for molecular diagnosis of infectious agents. PathoFinder has successfully participated in many EQA programs for respiratory pathogens. Details of these tests are available on request. We will keep participating in QCMD programs to ensure the quality, sensitivity and specificity our products.
- 14 viral + 4 bacterial pathogens in one assay
- As sensitive as monoplex Real Time PCR
- Contains a competitive internal amplification control
- Diagnosis within 6 hours
- Validated on QCMD panels
- CE-IVD labelled
